Welcome to our dedicated page for Aclaris Therapeutics SEC filings (Ticker: ACRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aclaris Therapeutics filings document a Nasdaq-listed clinical-stage biopharmaceutical issuer developing immuno-inflammatory disease candidates. The record includes 8-K disclosures for quarterly and annual financial results, Regulation FD presentations, clinical pipeline updates for ATI-052 and ATI-2138, and common stock sales under an amended and restated sales agreement.
Proxy materials describe board and shareholder voting matters, executive compensation, equity awards and governance procedures. The filings also identify ACRS common stock, Delaware incorporation, R&D spending, royalty revenue from Lilly and Sun Pharma license agreements and capital-structure disclosures tied to public equity financing.
RA Capital Management and affiliates reported a significant ownership position in Aclaris Therapeutics, Inc. RA Capital Healthcare Fund, L.P. directly holds 12,723,026 shares of Aclaris common stock. Based on 139,824,273 shares outstanding as of June 30, 2026, this represents 9.1% of the company’s common stock. RA Capital Management, L.P. serves as investment adviser to the Fund and has been delegated sole voting and dispositive power over these shares, while the Fund, RA Capital, Peter Kolchinsky, and Rajeev Shah each disclaim beneficial ownership except for purposes of Section 13(d) reporting.
Aclaris Therapeutics, Inc. entered into a Second Amended and Restated Sales Agreement on August 6, 2026 with Leerink Partners LLC and Cantor Fitzgerald & Co., allowing it to offer and sell shares of common stock from time to time through these firms as sales agents under a Form S-3 shelf.
Sales may be conducted as an “at the market offering” under Rule 415, with Leerink and Cantor using commercially reasonable efforts subject to Aclaris’ instructions. Aclaris will pay a 3.0% commission on gross proceeds, is not obligated to sell any shares, and the prior 2025 agreement allowed sales of up to $100.0 million of common stock.
Aclaris Therapeutics, Inc. has put in place an automatic shelf registration on Form S‑3 as a well‑known seasoned issuer, replacing its prior shelf. The base prospectus covers the potential offering and sale, from time to time, of an indeterminate amount of common stock, preferred stock, debt securities and warrants by the company and any selling securityholders.
The filing also includes a separate prospectus for an “at‑the‑market” equity program allowing Aclaris to issue and sell up to $150,000,000 of common stock through Leerink Partners LLC and Cantor Fitzgerald & Co. as sales agents under a sales agreement dated August 6, 2026. Net proceeds, if any, are intended primarily for research and development of its immuno‑inflammatory product candidates, working capital and general corporate purposes, with potential use for complementary acquisitions.
Aclaris is a clinical‑stage biopharmaceutical company focused on novel small and large molecule candidates for immuno‑inflammatory diseases, leveraging its KINect discovery platform. It is classified as a smaller reporting company, which allows reduced disclosure requirements under SEC rules.
Aclaris Therapeutics, Inc. reported Q2 2026 revenue of $1.629 million and a net loss of $21.505 million, bringing first‑half revenue to $3.625 million and net loss to $41.329 million. Performance reflects continued investment in immuno‑inflammatory programs including bosakitug, ATI‑052, modzatinib and ATI‑9494.
Research and development expenses were $18.066 million in Q2 and $33.723 million year‑to‑date, while general and administrative costs reached $6.048 million and $12.791 million. Other income of $2.733 million, mainly interest and non‑cash royalty income, partially offset a Q2 operating loss of $24.238 million.
Cash, cash equivalents and marketable securities totaled $170.6 million at June 30, 2026. Operating activities used $37.996 million of cash in the first half, largely balanced by $57.872 million from equity financing, including a March at‑the‑market sale; a further July ATM raised $40.2 million gross. Management states these resources fund operations for more than 12 months but anticipates ongoing losses and additional future capital needs.
Aclaris Therapeutics, Inc. reported financial results for the quarter and six months ended June 30, 2026 and provided a corporate and clinical update. For the second quarter, total revenue was $1.6 million and net loss was $21.5 million. For the first half of 2026, net loss was $41.3 million, with research and development expenses of $33.7 million driven mainly by ATI-052 and ATI-9494 development, and general and administrative expenses of $12.8 million.
As of June 30, 2026, Aclaris held $170.6 million in cash, cash equivalents and marketable securities and stated that this is expected to fund operations through the end of 2028. After quarter-end, it sold 7.3 million shares via its at-the-market program for $40.2 million in gross proceeds to support planned Phase 2b and proof-of-concept trials. The update highlighted upcoming placebo-controlled top line data from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis, a Phase 2 trial of bosakitug in atopic dermatitis, planned Phase 2b programs for ATI-052 and modzatinib, and an expected IND filing for ATI-9494.
Aclaris Therapeutics, Inc. reports that Chief Scientific Officer Roland Kolbeck had 36,375 restricted stock units vest and convert into an equal number of common shares on August 1, 2026. Of these, 12,385 shares were withheld by the company at $5.20 per share to satisfy tax withholding obligations. Following the transactions, Kolbeck retains 109,125 restricted stock units, which vest in four equal installments on the first, second, third and fourth anniversaries of August 1, 2025, conditioned on continued service.
Aclaris Therapeutics director Anand Mehra reported routine equity compensation activity. On June 4, 2026, he received 10,987 restricted stock units and a stock option for 42,350 shares of common stock at an exercise price of $4.71 per share, both granted at no cash cost.
The option vests in twelve equal monthly installments starting on July 4, 2026, while the 10,987 restricted stock units are scheduled to vest on June 4, 2027, subject to his continuous service. On June 5, 2026, 11,580 previously granted restricted stock units vested and were exercised into 11,580 shares of common stock, bringing his direct common stock holdings to 726,403 shares.
Aclaris Therapeutics director Andrew N. Schiff reported routine equity compensation and an RSU vesting and conversion. On June 5, 2026, 11,580 restricted stock units vested and were converted into 11,580 shares of common stock, bringing his directly held common shares to 25,540.
On June 4, 2026, he received 10,987 new restricted stock units and a stock option for 42,350 shares at an exercise price of $4.71 per share, both granted under company equity plans. The option vests in twelve equal monthly installments starting July 4, 2026, and the new RSUs vest on June 4, 2027, subject to continuous service.
A separate indirect position of 434,455 common shares is held by Aisling Capital IV LP and related entities, over which Aisling GP, Aisling Partners, and their managers share voting and dispositive power. Dr. Schiff disclaims beneficial ownership of these Aisling-held shares except to the extent of his pecuniary interest.
Aclaris Therapeutics director Christopher P. Molineaux reported routine equity compensation activity. On June 4, 2026, he received 10,987 restricted stock units and 42,350 stock options with an exercise price of $4.71 per share. On June 5, 2026, 11,580 previously granted RSUs vested and converted into common stock, bringing his direct common share holdings to 69,536.
Humphries William D. reported acquisition or exercise transactions in this Form 4 filing.
Aclaris Therapeutics director William D. Humphries reported equity compensation activity. On June 4, 2026, he received grants of 10,987 restricted stock units and 42,350 stock options, each option exercisable at $4.71 per share. The RSUs vest in a single installment on June 4, 2027, and the options vest in twelve equal monthly installments starting July 4, 2026, subject to continuous service.
On June 5, 2026, 11,580 previously granted restricted stock units vested and were settled into 11,580 shares of common stock. Following these transactions, Humphries directly held 45,105 shares of Aclaris common stock, reflecting routine director compensation rather than open-market buying or selling.